Trial Profile
A Prospective, Randomized, Double-blind, Placebo-controlled, Evaluation of the Safety, Efficacy and Pharmacokinetics of MICARDIS (Telmisartan) in Children and Adolescents With Hypertension After Four Weeks of Treatment
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Telmisartan (Primary)
- Indications Hypertension
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 27 Oct 2010 New trial record